Research Topics
Genomes and GenesSpecies | Man Chiu PoonSummaryAffiliation: University of Calgary Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Hemophilia management in transfusion medicineMan Chiu Poon
The Department of Medicine and The Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
Transfus Apher Sci 46:299-307. 2012....
Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombastheniaM C Poon
Departments of Medicine, Pediatrics, and Oncology, University of Calgary and Foothills Hospital, Calgary, Alberta, Canada
Blood 94:3951-3. 1999..No adverse effects of rFVIIa were observed. Although the number of patients is small, our study suggests that rFVIIa may be an alternative to platelet transfusions in patients with a severe congenital thrombocytopathy...- Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agentsMan Chiu Poon
University of Calgary, Southern Alberta Hemophilia Clinic, Calgary Health Region, Canada
Semin Hematol 43:S33-6. 2006..glanzmann-reg.org) data collection tool. Data collection will begin in 2005 and continue for up to 6 years. Patients of all ages from any country are eligible for inclusion... - The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disordersMan Chiu Poon
Department of Medicine, University of Calgary, Calgary, Alberta, Canada
Transfus Med Rev 21:223-36. 2007..For GT patients undergoing surgery and for treatment and prevention of bleeding in thrombocytopenic patients, the optimal rFVIIa regimen remains to be defined... - 2B or not to be--the 45-year saga of the Montreal Platelet SyndromeMan Chiu Poon
Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
Thromb Haemost 104:903-10. 2010..This paper will review the 45-year saga of Montreal Platelet Syndrome, a story that highlights the value of revisiting a rare diagnosis to look for a more common explanation... - Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international surveyM C Poon
Centre d Hémophiles, AP HP Hôpital Bicêtre, Le Kremlin Bicetre, France
J Thromb Haemost 2:1096-103. 2004..Anecdotal reports suggest recombinant factor (rF)VIIa might be a therapeutic alternative in these situations... - Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?Man Chiu Poon
Foothills Medical Centre, 1403 29th Street NW, Calgary, AB T2N 2T9, Canada
Curr Hematol Rep 2:139-47. 2003..If rFVIIa is used, unresolved issues include optional dosage, dosing interval, and whether rFVIIa is best used alone or in conjunction with platelet transfusion... - Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance studyMan Chiu Poon
University of Calgary, Alberta, Canada
Thromb Haemost 87:431-5. 2002..No other serious adverse events, including thrombotic episodes, were reported. To the best of our knowledge, this is the first formal report of recovery and inhibitor formation on rFIX in a peer-reviewed manuscript form... - Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombastheniaM C Poon
Hemophilia Hemostasis Centres in Canada
Semin Hematol 38:21-5. 2001.... - Use of recombinant factor VIIa in hereditary bleeding disordersM C Poon
Division of Hematology and Hematologic Malignancies, Department of Medicine, Southern Alberta Hemophilia Clinic, University of Calgary, Alberta, Canada
Curr Opin Hematol 8:312-8. 2001..With expanding indications and more widespread use, thromboembolic complications must be carefully monitored, especially in patients at risk for thromboembolism. The high cost of this drug may be a limiting factor... - Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders GroupM C Poon
Department of Medicine, University of Calgary and Foothills Hospital, Alberta, Canada
Blood Coagul Fibrinolysis 11:S55-68. 2000..Analysis of data from this larger population will allow better comprehension of the role of NovoSeven in these disorders, and assist in the design of formal studies to address issues associated with the treatment of these disorders... - Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancerRussell D Hull
University of Calgary, Calgary, Alta, Canada
Am J Med 119:1062-72. 2006..Low-molecular-weight heparin, body-weight adjusted, avoids anticoagulant monitoring and has been shown to be more effective than vitamin-K-antagonist therapy... - The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutationShannon C Jackson
Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Calgary, Calgary, AB, Canada
Blood 113:3348-51. 2009..Thus, in reevaluating this kindred, we determined that patients with MPS have type 2B VWD with the V1316M VWF mutation... - Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literatureShannon Jackson
Division of Hematology, Department of Medicine, University of Calgary, Alberta, Canada
Am J Hematol 78:142-50. 2005..Large randomized-controlled studies enrolling patients from various ethnic backgrounds will be necessary to determine the response rate and mechanism of response and to gain a better understanding of the pathogenesis of ITP... 
Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombastheniaMan Chiu Poon
Department of Medicine, University of Calgary, Alberta, Canada
Vasc Health Risk Manag 3:655-64. 2007..This more "optimal regimen" derived from a recent International Survey needs confirmation with larger studies. What the optimal regimen for surgical coverage is remains unresolved...- 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaTom Bowen
Departments of Medicine and Paediatrics, University of Calgary, Calgary, Alberta, Canada
Allergy Asthma Clin Immunol 6:24. 2010.... - Low oxygen saturation by pulse oximetry may be associated with a low oxygen affinity hemoglobin variant, hemoglobin TitusvilleRebecca Deyell
Department of Pediatrics, University of Calgary and Calgary Health Region, Calgary, AB, Canada
J Pediatr Hematol Oncol 28:100-2. 2006..Early recognition of abnormal hemoglobin variants in asymptomatic patients may avoid extensive, unnecessary medical investigations... - Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndromeRussell D Hull
University of Calgary, Calgary, AB, Canada
Am J Med 122:762-769.e3. 2009..Home-LITE compared long-term treatment at home with tinzaparin or usual care in terms of efficacy, safety, patients' treatment satisfaction, incidence of post-thrombotic syndrome, and associated venous leg ulcers... - Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversalDar Dowlatshahi
Department of Medicine, Division of Neurology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa Hospital Civic Campus, Room C2182, 1053 Carling Avenue, Ottawa, Ontario, Canada, K1Y 4E9
Stroke 43:1812-7. 2012..Given the lack of randomized controlled trial evidence of efficacy, and the potential for thrombotic complications, we aimed to determine outcomes in patients with aaICH treated with PCC... - Long term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpuraShannon C Jackson
Division of Hematology, Department of Medicine, Foothills Medical Centre, 1403 29th Street N W, Calgary, AB, T2N 2T9, Canada
Int J Hematol 88:212-8. 2008..Although the prevalence of H. pylori is low, H. pylori positive Canadian patients with ITP may benefit from a trial of H. pylori eradication therapy as a safe and effective means to achieve long term platelet response... - Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary AngioedemaTom Bowen
Department of Medicine and Paediatrics, University of Calgary, Alberta, Canada
Ann Allergy Asthma Immunol 100:S30-40. 2008..We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) in 2004... - Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of riskDenis Cournoyer
Department of Medicine, McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada
J Am Soc Nephrol 15:2728-34. 2004.... - Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harmsRussell D Hull
University of Calgary, Calgary, AB, Canada
Am J Med 120:72-82. 2007..We evaluated the effectiveness and safety of long-term LMWH compared with vitamin K antagonist therapy in a broad spectrum of patients with proximal vein thrombosis... - Aminoglycoside suppression of nonsense mutations in severe hemophiliaPaula D James
Department of Medicine, Queen's University, Kingston, Ontario, Canada K7L 3N6
Blood 106:3043-8. 2005..This study, however, does provide a proof of principle, suggesting that ribosomal interference with a less toxic agent may be a potential therapeutic mechanism for severe hemophilia patients with nonsense mutations...